The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses results of the IMpower010 trial (NCT02486718) in patients with version 7 TNM, stage 1b resected non-small cell lung cancer (NSCLC). All patients underwent adjuvant chemotherapy treatment, with some patients randomized to also receive atezolizumab immunotherapy for one year. The primary endpoint of the trial was disease-free survival (DFS), and there was a clear benefit observed in the PDL1-positive group, findings that can be considered practice-changing. This was discussed at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
